

ONLINE SUPPLEMENT.

Supplementary Table 1. The individual disease domains of the composite measures (CPDAI, MDA, DAPSA, cDAPSA).

	CPDAI	MDA \geq 5/7 VLDA=MDA 7/7	DAPSA	cDAPSA
Pain VAS		✓	✓	✓
PtGA VAS		✓	✓	✓
TJC 68	✓	✓	✓	✓
SJC 66	✓	✓	✓	✓
LEI	✓	✓		
PASI	✓	✓		
BSA		✓		
Dactylitis digit count	✓			
BASDAI	✓			
ASQoL	✓			
HAQ-DI	✓	✓		
DLQI	✓			
CRP			✓	

CPDAI: Composite Psoriatic Disease Activity Index; MDA: Minimal Disease Activity; VLDA: Very Low Disease Activity; DAPSA: Disease Activity index for PSoriatic Arthritis; cDAPSA: clinical DAPSA; PtGA VAS: Patient global disease activity by visual analogue score (VAS); TJC: tender joint count; SJC: swollen joint count; LEI: Leeds Enthesitis Index; PASI: Psoriasis Area Severity Index; BSA: Body Surface Area; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASQoL: Ankylosing Spondylitis Quality of Life questionnaire; HAQ-DI: Health Assessment Questionnaire-Disability Index; DLQI: Dermatology Life Quality Index; CRP: C-reactive protein.

Supplementary Table 2. Patient and disease characteristics comparing between those in CPDAI remission versus those with CPDAI >2.

Total number of patients: 222	CPDAI \leq 2	CPDAI>2	p value
Number of patients (%)	67 (30.2)	155 (69.8)	
Mean age \pm SD	51.6 \pm 12.2	50.4 \pm 12.4	0.51 *
Gender (male, n (%))	44 (65.7)	72 (46.5)	0.01 †
TJC (0-68)	0.5 \pm 0.9	4.6 \pm 5.0	<0.01 ‡
SJC (0-66)	0.1 \pm 0.3	1.6 \pm 3.9	<0.01 ‡
LEI (0-6)	0	0.4 \pm 0.7	<0.01 ‡
PASI (0-72)	1.6 \pm 2.2	3.4 \pm 3.9	<0.01 ‡
BSA (0-100)	1.6 \pm 2.6	4.1 \pm 6.5	<0.01 ‡
Dactylitis digit count (0-20)	0	0.3 \pm 0.8	0.01 *
BASDAI (0-10)	1.8 \pm 1.3	3.6 \pm 2.0	<0.01 ‡
ASQoL (0-18)	1.8 \pm 3.2	5.7 \pm 5.1	<0.01 ‡
HAQ-DI (0-3)	0.4 \pm 0.6	0.9 \pm 0.7	<0.01 ‡
DLQI (0-30)	1.6 \pm 2.7	3.5 \pm 5.2	<0.01 ‡
Inflammatory back pain, n (%)	18 (26.9)	102 (65.8)	<0.01 †
Pain VAS (0-10)	2.2 \pm 2.0	4.2 \pm 2.7	<0.01 ‡
PtGA VAS (0-10)	2.0 \pm 1.8	4.2 \pm 2.6	<0.01 ‡
CRP (mg/L)	3.9 \pm 7.4	5.3 \pm 7.9	0.23 *
DAPSA \leq 4, n (%)	30 (44.8)	14 (9.0)	<0.01 †
cDAPSA \leq 4, n (%)	36 (53.7)	16 (10.3)	<0.01 †
VLDA (MDA 7/7), n (%)	16 (23.9)	4 (2.6)	0.01 **

Unless otherwise stated (n (%): number and (percentage) of patients), results are presented as mean \pm SD.

*By *t*-test; †By Chi-squared test; ‡By Wilcoxon's rank sum test; **By Fisher's exact test.

CPDAI: Composite Psoriatic Disease Activity Index; TJC: tender joint count; SJC: swollen joint count; LEI: Leeds Enthesitis Index; PASI: Psoriasis Area Severity Index; BSA: Body Surface Area; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; ASQoL: Ankylosing Spondylitis Quality of Life questionnaire; HAQ-DI: Health Assessment Questionnaire-Disability Index; DLQI: Dermatology Life Quality Index; PtGA VAS: Patient global disease activity by visual analogue score; CRP: C-reactive protein; DAPSA: Disease Activity index for Psoriatic Arthritis; cDAPSA: clinical DAPSA; VLDA: Very Low Disease Activity (Minimal Disease Activity (MDA) 7/7).

